The Medtronic bladder control therapy delivered by the NURO™ system helps you regain bladder control with nerve stimulation. The therapy is administered in your doctor’s office over the course of 12 weeks.
This therapy starts with a series of 12 weekly, 30-minute sessions delivered at your doctor’s office.
A: This therapy targets the tibial nerve to help you regain control of your bladder.
A: The NUROTM system stimulates the tibial nerve through an acupuncture-like needle placed in the skin near your ankle.
A: It’s thought that bladder control problems are caused by miscommunication between the bladder and the central nervous system.1 The tibial nerve connects to nerves responsible for bladder function.
A: PTNM can be an effective overactive bladder (OAB) treatment that's clinically proven to restore‡ bladder function.2 It doesn't cause side effects like medications can,3 and it doesn’t require self-catheterization.5
A: The most common side effects are temporary and include mild pain or skin inflammation at or near the stimulation site.
A: Medicare and many private insurance companies cover this therapy.
A: Following your initial treatment of 12 weekly, 30-minute sessions, you can continue with maintenance therapy. When you are on maintenance therapy, treatments occur every three to four weeks rather than every week. These sessions are exactly the same as the first 12, and can be scheduled at a time that is convenient for you.
Evidence shows that Medtronic bladder control therapy by the NURO™ system is an effective treatment for people with OAB.1 Highlights from recent research include the following results:
Evaluated using the Overactive Bladder Symptom Quality of Life Questionnaire (OAB-q)
Evaluated using the Patient Perception of Bladder Condition (PPBC) scale
Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following PTNM treatment.
Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin N Am. 2006;33:491-501.
Kobashi K, Khandwala S, MacDiarmid S, et al. A Prospective Study to Evaluate Efficacy with the NURO Percutaneous Tibial Neuromodulation System in Drug Naïve Patients with overactive bladder syndrome (OAB). Presented at the American Urological Association 2018 Annual Meeting. Journal of Urology. 2018;199(4) Supplement, Page e987.
Peters, K. M., S. A. Macdiarmid, et al. (2009). “Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.” J Urol. 182(3): 1055-1061.
Kobashi K, Sand P, Margolis E, et al. Increasing therapy effect over twelve weeks with the NURO™ percutaneous tibial neuromodulation system in drug naïve patients with overactive bladder syndrome (OAB). Presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2019 Winter Meeting. Neurourology and Urodynamics 2019; 38(S1), Page S79.
Visco A, Brubaker L, Richter HE et al. Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence. New Engl J Med. 2012;367(19):1803-1813.
Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.